



Press Release

SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

Martinsried/Munich, Germany, February 8, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that Dr. Robert Phelps has joined the Company as Head of Business Development & Licensing.

Most recently, Dr. Phelps has been Director Business Development & Licensing at PARI Pharma GmbH, Munich, Germany, where he was responsible for all in- and out-licensing activities pertaining to the company's aerosol delivery technologies and pharmaceutical development programs. Previous to that, he has held business development and licensing positions at various biotechnology and pharmaceutical companies such as Bavarian Nordic A/S, Patheon UK Ltd., Evotec AG, and Hexal Gentech ForschungsGmbH. He received his PhD in 1997 in biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institut in Germany. Subsequently, he held a research position as a post-doctoral fellow at the Medical University of South Carolina, Charleston (SC), USA, until 1999.

"Robert is an accomplished, skilled executive with more than ten years experience in business development and licensing in the biotech and pharma industry," said Dr. Peter Buckel, CEO of SuppreMol. "He will be a valuable addition to our team as we have reached a stage with excellent development and marketing opportunities for our lead product SM101. Besides, we are also planning an expansion of our pipeline by acquisitions or in-licensing."

"I am very happy to join SuppreMol," Dr. Robert Phelps added. "The Company has been highly successful in securing substantial funds and advancing its products to the clinic. Already, various potential corporate partners have expressed great interest in SuppreMol's product candidates."

###

Notes to Editors

About SuppreMol

SuppreMol is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases. The company is pioneering the development of soluble Fcγ-Receptors (sFcγRs), which are recombinant autologous therapeutic proteins with a proven strong immunosuppressive potential. The company plans to develop sFcγRs for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and other autoimmune conditions.

SuppreMol was founded in 2002 as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize for Chemistry in 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. The Company has raised EUR 19.7 million in two financing rounds since May 2006 and received a EUR 1.75 million “Innovative Therapeutics” grant from the BMBF in March 2007 as well as additional funding by BMBF's “Bio-Chance” program in 2009.

Contact

Dr. Peter Buckel, CEO
SuppreMol GmbH
Am Klopferspitz 19
82152 Martinsried/München
Germany
tel +49 (0)89 30 90 50 680
fax +49 (0)89 30 90 50 68 68
info@suppremol.com
www.suppremol.com